About

Our Company

Overview

SEED Therapeutics is a clinical-stage biotechnology company pioneering the discovery of molecular glues to treat diseases once considered untreatable. Our therapies harness the ubiquitin-proteasome system (UPS), a natural cellular process, to degrade harmful proteins that lack traditional druggable pockets.

Backed by a Nobel laureate and world-renowned experts in targeted protein degradation (TPD), SEED is building a new generation of medicines against the 80% of disease-causing proteins that current drugs cannot reach.

At the core of our innovation is RITE3™, our proprietary discovery platform that systematically identifies novel E3 ligases to target unfolded or mutant proteins across oncology, neurodegeneration, immunology, and virology. SEED’s platform and pipeline have positioned the company as a global leader in TPD, as recognized in two Nature review articles in 2024.

Our Team

What Sets Us Apart

A Next-Gen TPD Platform: RITE3™

SEED’s RITE3™ platform is engineered to overcome the toughest challenges in molecular glue discovery. While most companies rely on just two well-known E3 ligases (Cereblon and VHL), SEED’s TPD2.0 approach systematically selects from over 600 E3s, both HECT and RING domain classes, to precisely target difficult proteins.

  • Multidimensional design: integrates structural biology, cell-based assays, and proteomics
  • Broad scope: successfully applied to nine active programs using six novel E3 ligases
  • Disease focus: includes oncology, neurodegeneration, immunology, and virology

As highlighted in Nature Biotechnology (2024), “SEED Therapeutics is among those letting other E3 ligases shine.”

Our Team

SEED’s Co-Founders provide strategic scientific leadership that drives company value. Key Co-Founders and members of the leadership team meet regularly to guide decisions across platform development, target prioritization, and clinical and regulatory strategy. Their deep and complimentary expertise ensures that SEED’s pipeline is built on validated biology with a clear path to the clinic. By rigorously vetting assumptions and aligning programs with the most promising therapeutic opportunities, they help de-risk medicine development and accelerate value creation.

Leaders

Management

Board of Directors